Furthermore, Ang II blocking drugs, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), have been also found to reduce the development of NAFLD in large amounts of literature [18–23]. The gene discussed is AGT; the disease is metabolic dysfunction-associated steatotic liver disease.